Preclinical and clinical strategies for development of telomerase and telomere inhibitors

S. Sharma, E. Raymond, H. Soda, D. Sun, S. G. Hilsenbeck, A. Sharma, E. Izbicka, B. Windle, D. D. Von Hoff

Research output: Contribution to journalReview article

69 Scopus citations

Abstract

Background: Telomerase is an important enzyme whose activity has been convincingly demonstrated in humans recently. It is required for maintenance of ends of chromosomes (telomeres) during cell division. Since its presence has been selectively demonstrated in dividing cells including tumor cells, it has generated considerable excitement as a potential anti-cancer strategy. Design: In this article, we review the current relevant biology of the enzyme, the challenges encountered in the preclinical phase of target development and the current efforts that focus on telomeres and telomerase as therapeutic targets. We also speculate on the potential toxicities and mechanisms of resistance that may be encountered during use of such therapies.

Original languageEnglish (US)
Pages (from-to)1063-1074
Number of pages12
JournalAnnals of Oncology
Volume8
Issue number11
DOIs
StatePublished - Nov 1 1997
Externally publishedYes

    Fingerprint

Keywords

  • Cancer
  • Chemotherapy
  • Telomerase
  • Telomeres

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Sharma, S., Raymond, E., Soda, H., Sun, D., Hilsenbeck, S. G., Sharma, A., Izbicka, E., Windle, B., & Von Hoff, D. D. (1997). Preclinical and clinical strategies for development of telomerase and telomere inhibitors. Annals of Oncology, 8(11), 1063-1074. https://doi.org/10.1023/A:1008206420505